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immune compromised hosts, and on the protective efficacy. A total of 35
studies in 10 countries involving over 6000 subjects, including 500 children
and 480 controls, have been performed. Clinical experience and postmar-
keting surveillance since licensure in 1994, has shown the vaccine to be well
tolerated, rarely causing mild, transient systemic and hardly any local
reactions. Protective antibody titers (> 1=20 mlUIml) are obtained one
month after a 1st dose in 95-100% ofhealthy adult vaccinees. After a single
dose protective antibody levels (incl. neutralising antibodies) develop from
day 9 onward and by day 15 over 90% ofvaccinees are protected. There is no
clinical relevant interference from concomitant use of influenza vaccine,
yellow fever or other travel vaccines or of immunoglobulins. In a double-
blind, placebo-controlled field trial in children under 5 year old in an
endemic area a protective efficacy of> 95% was found. This aluminium-
free, virosome formulated hepatitis A vaccine is very well tolerated, is highly
immunogenic and confers long-lasting (> 20 years) protection against
hepatitis A.
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Virosomes, a new type of antigen delivery system. are reconstituted
influenza virus envelopes, composed mainly by a phospholipid bilayer and
intercalated influenza haemagglutinin. In the case of the today only com-
mercialised types ofvirosome vaccines against hepatitis A and influenza egg
yolk lecithin and synthetic cephalin is added to enlarge the surface of the
virosome globule. By the nature of their composition virosomes do not
stimulate inflammatory reactions upon parenteral or mucosal administra-
tion. Unlike alumininium-adsorbed vaccines virosomes can, therefore, be
injected intradermally. With the still fusion-active haemagglutinin mole-
cules on the surface the virosomes, including any attached vaccine antigens,
bind to and are taken up by immuneompetent cells (macrophages) in the
muscle, in the skin and in the mucosa. Clinical data are presented on
intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administra-
tion of a virosome formulated hepatitis A vaccine and on the i.m. and
intranasal (i.n.) administration of a virosome formulated subunit influenza
vaccine. The local tolerability is excellent for all four routes. The i.d.
administration of 0.1 ml, which gave protective, although somewhat
lower antibody titers than the full 0.5 ml i.m. dose, will allow a considerable
reduction in immunisation costs. This could be important for the hep:atitis A
endemic developing countries aiming to immunize in the near future large
population groups. The i.n. immunisation against influenza elicites with the
help ofsmall amounts ofheat-labile E. coli toxin as adjuvant strong humoral
and mucosal immune responses, demonstrating the feasibility of mucosal
immunisation with this new type of antigen delivery system.
IND16 - bioMerieux: Are molecular diagnostics possible
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Microbiology testing (MT) is performed for disease management and health
management. Dealing with individual patients, clinicians use MT primarily
to adjust treatments and set preventive measures in case of communicable
diseases such as MRSA or tuberculosis. For both aims, time to results is a big
issue. Molecular technology such as DNA fingerprinting, automated PCR,
hybridisation technologies, and, soon, DNA chips, has allowed to shorten
significantly the time to result in MT. so that results are made available the
day of the sampling. This performance provides clinical benefit, economic
benefit and patient satisfaction. Rapid results were unusual with the con-
ventional techniques, since microscopic exam is rarely fully diagnostic, and
cultures require typically an overnight incubation or more. Modem rapid
techniques are especially efficient with regard to time to result when dealing
with slow growing or fastidious organisms like M. tuberculosis. L. pneumo-
phila. C. trachomatis or viruses. However, rapid testing has to be made
available on a daily basis: if not, the benefit of promptitude in the testing
would be lost. Examples ofcombined economic and clinical values ofrapid
testing include tuberculosis, Chlamydia prevention and control, detectionl
eradication of H. pylori in gastro-duodenal diseases, and safety of blood
supply.
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Respiratory tract infections arc a frequent came of physician visits and are
among the commonest reasons for antibiotic prescriptions. Lower respira-
tory tract infections such as acute exacerbations of chronic bronchitis,
community-acquired pneumonia and hospital acquired pneumonia are
associated with considerable morbidity and mortality and have a major
impact on society and health care economics. Over the past decade. it has
become apparent that a number ofissues must be considered whcn planning
treatment regimens for patients with such lower respiratory tract infections.
These include: the significance of the disease, the increasing prevalence of
resistant pathogens, the possibility of copathogenicity and the realization
that inappropriate initial therapy in severely ill patients with pneumonia can
result in increased mortality. The fluoroquinolones are an important addi-
tion to our therapeutic armamentarium. Newer agents in particular offer
improved activity against the pneumococcus while retaining activity against
most gram negative pathogens. In addition to their reasonably broad
spectrum of activity they offer the advantage of monotherapy for most
patients. This is associated with compliance and cost benefits. The role for the
quinolones in selected respiratory tract infections is becoming quite clear and
will be discussed during the debate.
Influenza and other respiratory viruses
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Two classes of anti-influenza agents, M2 ion channel blockers and neur-
aminidase (NA) inhibitors, have documented effectiveness in prevention and
treatment ofinfluenza. Amantadine and rimantadine are orally bioavailable
inhibitors of influenza A virus replication. Therapeutic use speeds recovery
from acute, uncomplicated influenza by 1-2 days ifbegun early in the course
of illness. However, it remains unclear whether treatment is beneficial in
more severe infections or reduces the risk of complications. Rimantadine'ls
associated with a lower risk of CNS adverse effects than amantadine.
Resistance due to single amino acid changes in the M2 protein confers
high level cross-resistance. Rapid emergence of drug-resistant variants
occurs in up to 30% of treated persons, and transmission of these has
caused failures of drug prophylaxis in family contacts and nursing home
residents.
Zanamivir and oseltamivir carboxylate (GS4071) are potent. selective
influenza neuraminidase inhibitors in vitro but have different pharmacoki-
netic properties. Both included zanamivir and the oral prodrug oseltamivir
(GS4104) are therapeutically effective in uncomplicated influenza. Twice
daily inhaled zanamivir treatment shortens symptoms and reduces lower
respiratory tract complications in acute influenza in adolescents and adults.
Twice daily oral oseltamivir is effective in treating acute influenza in adults
and children and also reduces complications leading to antibiotic use.
Treatment efficacy in patients with asthma and COPD is under study.
Both agents are also effective for seasonal or post-exposure prophylaxis of
influenza when used once daily. One instance of resistance emergence to
zanamivir has been recognized in an immunocompromised host, and
GS4071 resistant variants have been recovered very uncommonly « 2%)
from immunocompetent patients. However, these variants show reduced
neuraminidase function and lower replication and pathogenicity than wild-
type virus in animal models. Neuraminidase inhibitors provide significant
advances in the management of influenza A and B virus infections.
